OTCMKTS:KALTF Claritas Pharmaceuticals (KALTF) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free KALTF Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume18,081 shsAverage Volume9,705 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartStock AnalysisChart Get Claritas Pharmaceuticals alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Claritas Pharmaceuticals Stock (OTCMKTS:KALTF)Claritas Pharmaceuticals, Inc. engages in the development of next generation cannabinoid therapeutics. It also offers development programs for bone fracture healing, osteogenesis imperfecta, osteoporosis, and osteoporosis in Prader-Willi syndrome. The company was founded by Seth Yakatan on October 15, 2004 and is headquartered in San Rafael, CA.Read More Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> KALTF Stock News HeadlinesJuly 6, 2023 | finance.yahoo.comDPHAY - Dechra Pharmaceuticals PLCJune 22, 2023 | marketwatch.comAnimal Health Active Pharmaceutical Ingredients Market Research Insights with Upcoming Trends Segmentation, Opportunities and Forecast to 2030April 28, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.June 21, 2023 | finance.yahoo.comACXP - Acurx Pharmaceuticals, Inc.April 27, 2023 | marketwatch.comPharmaceutical Lecithin Market Size, Growth, Outlook, Share, Segmentation Analysis, Revenue And Forecast 2031March 17, 2023 | marketwatch.comGeneric Drugs Market Share, Segmentation and Forecast 2023-2028February 14, 2023 | marketwatch.com2023 Pharmaceutical CDMO Services Market Segmentation and Targeting: Strategies for Success Forecast till 2028February 13, 2023 | marketwatch.com2023 Mifepristone Market Segmentation and Targeting: Strategies for Success Forecast till 2028April 28, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.January 19, 2023 | marketwatch.comRadioimmunotherapy Treatment Market Geographical Segmentation By Forecast Revenue 2023-2028January 12, 2023 | finance.yahoo.comClaritas Pharmaceuticals, Inc. (CLAZF)January 5, 2023 | marketwatch.comOnline Pharmaceuticals Market Evolution Segmentation and Insight of Trends 2023 to 2028 with Top Countries DataNovember 30, 2022 | marketwatch.comAnalgesics Market Global Investor, Latest Trends, Industry Growth, Size, Segmentation, Future Demands, by Regional Forecast to 2028September 30, 2022 | marketwatch.comPharmaceutical Sachet Market In 2022 : Industry Growth, Top Players, Segmentation and Forecast to 2028 with Top Countries DataSeptember 22, 2022 | finance.yahoo.comNew Claritas Report Reveals that the U.S. Hispanic Population Grew 89% Since 2000 – and Will Exceed 74 Million Consumers by 2028September 13, 2022 | reuters.comClaritas Pharmaceuticals IncMay 11, 2022 | investing.comClaritas Pharmaceuticals Inc (CLAS)March 12, 2022 | benzinga.comKaya Now Appoints Stormy Simon As A Director Of The BoardFebruary 22, 2022 | finance.yahoo.comClaritas Announces Receipt of Comments from Australian Ethics Committee Regarding the Company’s Phase 1 Clinical Study of R-107 and Closing of FinancingFebruary 9, 2022 | finance.yahoo.comClaritas Anticipates Response from Australian Ethics Committee by February 18, 2022January 26, 2022 | finance.yahoo.comClaritas Announces Revised, Improved Terms for Initial Tranche of Financing with Alumina PartnersJanuary 17, 2022 | finance.yahoo.comClaritas Announces Letter of Intent to Acquire Worldwide Rights to R-107 for Treatment of Wound Healing, Skin Ulcers and Severe BurnsJanuary 17, 2022 | finance.yahoo.comClaritas Announces New Registered and Records Office Address, Confirms its Management and Directors and Announces Terms of Initial Tranche of Equity Financing with Alumina PartnersJanuary 12, 2022 | seekingalpha.comClaritas Pharmaceuticals signs $5M equity financing dealJanuary 12, 2022 | finance.yahoo.comClaritas Secures $5 Million Equity Financing Facility with Alumina Partners (Ontario) Ltd.December 22, 2021 | finance.yahoo.comClaritas to Develop R-107 for Treatment of PPHN, a Potentially Fatal Pulmonary Disorder in NewbornsDecember 21, 2021 | finance.yahoo.comClaritas Completes Acquisition of Exclusive Worldwide Rights to Develop and Commercialize R-107 for Pulmonary DiseaseSee More Headlines Receive KALTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Claritas Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/29/2013Today4/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:KALTF Previous SymbolOTCMKTS:QUEZF CUSIPN/A CIKN/A Webkalytera.co Phone(888) 861-2008FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesRobert Edward FarrellChairman, President & Chief Executive OfficerVictoria Diana RudmanChief Financial Officer, Secretary & TreasurerNedira FrenkelDirector-Business DevelopmentKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors KALTF Stock Analysis - Frequently Asked Questions How were Claritas Pharmaceuticals' earnings last quarter? Claritas Pharmaceuticals, Inc. (OTCMKTS:KALTF) posted its quarterly earnings data on Friday, November, 29th. The company reported ($0.40) earnings per share for the quarter. When did Claritas Pharmaceuticals' stock split? Shares of Claritas Pharmaceuticals reverse split on Friday, July 23rd 2021. The 1-20 reverse split was announced on Friday, July 23rd 2021. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 23rd 2021. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Claritas Pharmaceuticals? Shares of KALTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:KALTF) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Claritas Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
